Corbus Pharmaceuticals Q2 EPS $(0.90) Beats $(1.26) Estimate
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals (NASDAQ:CRBP) reported a Q2 EPS of $(0.90), beating the analyst estimate of $(1.26) by 28.57%. This represents a 56.1% improvement over the $(2.05) loss per share from the same period last year.
August 06, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corbus Pharmaceuticals reported a Q2 EPS of $(0.90), beating the analyst estimate of $(1.26) by 28.57%. This is a significant improvement from the $(2.05) loss per share in the same period last year.
The better-than-expected EPS and significant year-over-year improvement indicate positive financial performance, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100